Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value

Impact · against what's priced in

The report of a 51.5% reduction in infections and a jump in patient compliance to 93.3% at Canada's largest cardiac centre provides material real-world evidence exceeding Phase 3 trial results. While the US market remains investigational, the operational evidence for point-of-care delivery removes a significant adoption barrier.

OBI+0.50: No priced-in read yet
In context: Real-world efficacy of 51.5% exceeds the 40.5% relative reduction seen in the LANTERN trial, while the shift to nurse-delivered care boosted compliance from 35.4% to 93.3%, addressing a key operational hurdle for scaling.
Read from the article alone

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value

OBINew
biotech▲15%
healthcare
canada
cardiac surgery
clinical trials
infections
medical devices

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value

What matters in this story

Medpace: 3 Key Takeaways for Long-Term Investors

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value

What matters in this story

Medpace: 3 Key Takeaways for Long-Term Investors

How each ticker is affected

Track these names every morning.

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

Telix Pharmaceuticals: The ITM Deal Could Strengthen The Long-Term Buy Case

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value

What matters in this story

Next reads from the same story arc

Medpace: 3 Key Takeaways for Long-Term Investors

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value

What matters in this story

Next reads from the same story arc

Medpace: 3 Key Takeaways for Long-Term Investors

How each ticker is affected

Track these names every morning.

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

Telix Pharmaceuticals: The ITM Deal Could Strengthen The Long-Term Buy Case

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01